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ABSTRACT
Background: Amyloid-beta protein (A) plays a key role in Alzheimer disease (AD) and is also
implicated in cerebral small vessel disease. Serum total homocysteine (tHcy) is a risk factor for
small vessel disease and cognitive impairment and correlates with plasma A levels. To determine
whether this association results from a common pathophysiologic mechanism, we investigated
whether vitamin supplementation–induced reduction of tHcy influences plasma A levels in the
Vitamin Intervention in Stroke Prevention (VISP) study.
Methods: Two groups of 150 patients treated with either the high-dose or low-dose formulation
of pyridoxine, cobalamin, and folic acid in a randomized, double-blind fashion were selected
among the participants in the VISP study without recurrent stroke during follow-up and in the
highest 10% of the distribution for baseline tHcy levels. Concentrations of plasma A with 40
(A40) and 42 (A42) amino acids were measured at baseline and at the 2-year visit.
Results: tHcy levels significantly decreased with vitamin supplementation in both groups. tHcy
were strongly correlated with A40 but not A42 concentrations. There was no difference in the
change in A40, A42 (p  0.40, p  0.35), or the A42/A40 ratio over time (p  0.86) be-
tween treatment groups. A measures were not associated with cognitive change.
Conclusions: This double-blind randomized controlled trial of vitamin therapy demonstrates a strong
correlation between serum tHcy and plasma A40 concentrations in subjects with ischemic stroke.
Treatment with high dose vitamins does not, however, influence plasma levels of A, despite their
effect on lowering tHcy. Our results suggest that although tHcy is associated with plasma A40, they
may be regulated by independent mechanisms. Neurology® 2009;72:268–272
GLOSSARY
A  amyloid-beta; AD  Alzheimer disease; BMI  body mass index; DBP  diastolic blood pressure; MMSE  Mini-Mental
State Examination; mRS  modified Rankin Scale; NIHSS  NIH Stroke Scale; SBP  systolic blood pressure; tHcy  total
homocysteine; VISP  Vitamin Intervention in Stroke Prevention study.
Amyloid -protein (A40, A42) deposition in the brain is a hallmark of Alzheimer disease
(AD) and is thought to be the cause of cognitive impairment and dementia.1 Reduction of A
production is a candidate approach for treatment and prevention of cognitive impairment and
dementia.2 Plasma total homocysteine (tHcy) levels are correlated with plasma A, although
the biologic importance of this association is uncertain.3-5 Plasma tHcy has been implicated as a
risk factor for small vessel cerebrovascular disease and the development of cognitive impair-
ment and dementia.6-8
There are several potential implications of these associations in relation to AD, cognitive
impairment, and microangiopathy. tHcy may increase the risk of AD by elevating A levels.
Alternatively, A may increase the risk of microangiopathic changes through elevation of tHcy
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levels. Neurotoxicity may be potentiated by
the dual elevation of both tHcy and A. Fi-
nally, tHcy and A may be markers of a
pathogenic mechanism and independent of
each other.
Since plasma tHcy levels are readily modifi-
able by high-dose vitamin supplementation, we
hypothesized that plasma A levels may also be
modifiable by vitamin supplementation. We
thus aimed to test whether this association re-
sults from a common pathophysiologic mecha-
nism between these biomarkers or if in fact they
represent independent processes.
The Vitamin Intervention in Stroke Pre-
vention (VISP) was a randomized controlled
trial designed to test the hypothesis that low-
ering tHcy levels with large doses of folic acid,
pyridoxine, and vitamin B12 would reduce the
incidence of recurrent stroke or myocardial
infarction.9 Although the study did not show
a benefit for the primary endpoint, tHcy was
successfully lowered with vitamin therapy.
We investigated plasma A as an add-on
component to the VISP study to test the hy-
potheses whether vitamin supplementation–
induced reduction of tHcy over 2 years
influences plasma A levels.
METHODS Subjects. Details of the VISP trial have been
published previously.9 Briefly, the VISP trial enrolled a total of
3,680 adults who 1) were within 120 days of a mild or moderate
ischemic stroke (modified Rankin Scale [mRS] score of  3); 2)
were 35 years or older; and 3) had a fasting tHcy level approximately
greater than the 25th percentile for patients with stroke. Subjects
were enrolled between September 1996 and December 2001 at 56
centers in the United States, Canada, and Scotland, and random-
ized to receive a high dose formulation (n  1,827) containing 25
mg of pyridoxine, 0.4 mg of cobalamin (B12), and 2.5 mg of folic
acid or the low dose formulation (n  1,853) of 200 mcg of pyri-
doxine, 6 mcg of cobalamin, and 20 mcg of folic acid.
Baseline VISP data included a standardized medical history,
demographic variables, body mass index (BMI), stroke symp-
toms questionnaire, systolic and diastolic blood pressures, and a
neurologic examination. Several scales which measure disability
and cognition were administered to all patients (mRS, NIH
Stroke Scale [NIHSS], Mini-Mental State Examination
[MMSE]),9 and serum levels of folate, B12 levels, and a lipid
profile were ascertained. tHcy levels were obtained while fasting
and after methionine loading.9
The assembly of the cohort for this substudy is shown in the
figure. We selected at random a group of 150 patients treated
with high dose formulation and another group of 150 patients
with low dose formulation (within sex and 10-year age strata)
among participants who did not have a recurrent stroke during
the trial and who were in the highest 10% of the distribution for
baseline tHcy levels, in order to maximize potential observed
treatment effect. The sample numbers were selected based on
power analysis and practical capacity for performing the out-
come measures. In the current study, we had 85% power to
detect an absolute difference of 7.5% in A levels with high dose
vitamin supplementation. Requirements for inclusion in the
pool of potential subjects were availability of the following at
both baseline and 2-year visits: blood samples, vitamin and tHcy
levels, and MMSE. Individuals with less than 75% compliance
by pill count were excluded. Plasma A levels were measured in
blood samples drawn at baseline and at the 2-year visit. This
study was performed with approval by the ethics committees of
all study institutions and administrative sites. Written informed
consent was obtained from every potential participant. This sub-
study was performed with approval and in accord with the
guidelines of our institutional review boards.
Blood collection. Blood was collected in polypropylene sterile
plunger tubes containing potassium ethylenediamine tetraacetic
acid. Samples were centrifuged at 1,380 g for 15 minutes, ali-
quoted with a protease inhibitor cocktail and frozen in dry ice,
and stored at 80°C.
Biochemical assays. Plasma tHcy was determined by high-
performance liquid chromatography, as detailed in our previous
studies.9-11 Plasma A40 and A42 concentrations were deter-
mined by sandwich ELISA using the BNT77 capture antibody
and C-terminal specific detector antibodies BA27 and BC05 as
previously described and validated.4,12 We have demonstrated
this ELISA system to detect A40 or A42 at concentrations as
low as 1 pmol/L and to detect both free and protein-bound
A.4,12 All biochemical analyses were performed without knowl-
edge of subjects’ clinical or radiographic information.
Statistical analyses. For univariate analysis, 2 tests were used
to compare two categorical variables and analyses of variance
were performed to compare continuous variables distributions
across groups. All p values were two-tailed and criterion for sig-
nificance was p  0.05.
To determine whether vitamin treatment affected plasma A
levels, we adopted a linear mixed effects model for the data lon-
gitudinally measured over the 2-year period.13 This technique
allows for analysis of time-independent and time-dependent
variables to identify associations with these variables as well as
their trajectories over time. The parameter estimates indicate
how much change in plasma A levels resulted from a one unit
change in each risk factor. Analyses were also performed using
the A42/A40 ratio, as it has been recently demonstrated that
this ratio may be associated with an increased risk of demen-
tia.14,15 For all models of the three outcome measures (A40,
A42, and A42/A40 ratio), we investigated the effects of age,
gender, clinical, and laboratory variables on change in plasma A
levels. Covariates that were associated with clinical scales in uni-
variate analysis (p  0.10) were considered in the final model.
RESULTS The baseline clinical and demographic
variables are presented in table 1. There were no sig-
nificant differences in clinical or demographic vari-
ables between the two groups. There were no
differences between A40 or A42 levels between
treatment groups at baseline (p  0.97 and 0.30,
respectively). The median follow-up interval was
24.0 months.
Levels of tHcy at 2-year follow-up declined in
both treatment groups (change in tHcy at 2 years
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4.73  8.98 in high treatment group and 1.66 
7.79 in the low treatment group; p  0.0001 and
p  0.009, respectively). Reduction of tHcy was sig-
nificantly greater in the high treatment group [
(time  treatment group)  0.1289; p  0.0001].
Baseline tHcy levels and tHcy levels at 2-year
follow-up were significantly correlated with A40
levels (r  0.25 and 0.29, respectively; p  0.0001
for both comparisons). However, tHcy levels were
not correlated with A42 levels at baseline (p 
0.50) or at 2-year follow-up (p  0.20).
Levels of A40, A42, and the A42-A40 ratio
at baseline and follow-up are shown in table 2. A40
levels did not significantly change over the treatment
period (  0.09, p  0.44) and there was no
significant difference in the change in A40 levels
between treatment groups (  0.14, p  0.40).
Similarly, there was no significant change in either
A42 levels or the A42-A40 ratio over time be-
tween treatment groups (p  0.35 and p  0.86)
(table 2).
There was no association between A40, A42
levels, or the A42/A40 ratio with MMSE at base-
line (p  0.10, p  0.62, and p  0.85, respectively)
or follow-up (p  0.28, p  0.74, and p  0.50,
respectively). A levels did not influence change in
MMSE over the treatment period.
DISCUSSION In this study, we sought to define the
relationship between plasma A levels and homocys-
teine lowering in a cohort of subjects from the ran-
domized controlled VISP trial.9 The current study
demonstrates a strong association between tHcy and
plasma A40 levels in subjects with ischemic stroke
in this longitudinal analysis. These findings confirm
and extend cross-sectional observational studies
which have previously reported this association.3-5
However, despite the association of tHcy levels with
A40, A40 levels were not influenced by vitamin
treatment.
The strength of this study stems from the fact that
subjects had randomized assignment to treatment
type and that these subjects were followed prospec-
tively for recurrent stroke and other cardiovascular
events over a 2-year period with complete follow-up
of all patients.
Elevated tHcy is a predictive factor for vascular
disease, including ischemic heart disease and stroke.16
Several studies have suggested that elevated tHcy is
also a risk factor for white matter disease,17 cognitive
impairment,17-20 and AD.6-8 These associations may
be explained by vascular21or direct neurotoxic22,23 ef-
fects of tHcy.
Elevated plasma concentrations of A are associ-
ated with microvascular disease in both population-
based epidemiologic studies and cohorts of subjects
with cognitive impairment.4,24,25 In vitro studies have
suggested direct physiologic or toxic effects of A on
the contractile/relaxation elements of the blood ves-
sel wall.26-28 Data regarding plasma A and the risk
of cognitive decline are conflicting. Cohort studies
have reported that elevated plasma A40 or A42
levels increase the risk of developing AD over 5–8
years,14,15,29 although a fourth found that plasma
A42 levels were not associated with cognitive de-
cline over 30 months.30 Other studies have found
low A40 or A42 levels associated with incident
AD14,15 or more rapid cognitive decline in AD sub-
jects.31 Finally, some have suggested that low con-
Figure Assembly of study sample from the Vitamin Intervention in Stroke
Prevention (VISP) cohort
Recruitment for the VISP cohort is described in detail elsewhere.9 Briefly, patients with a
presumptive diagnosis of acute ischemic stroke were screened. Patients with total homo-
cysteine levels (tHcy) that exceeded defined thresholds were randomized for treatment
with high- or low-dose vitamin therapy. A random sample of eligible subjects with the high-
est 10% of tHcy were included in the study.
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centrations of plasma A42 in combination with
increased concentrations of plasma A40 are asso-
ciated with an increased risk of cognitive impair-
ment and dementia.14,15
This study did not find a significant treatment
effect of high dose vitamins on plasma levels of A40
despite the effect of the high dose vitamins on lower-
ing tHcy. This suggests that although tHcy is associ-
ated with plasma A40, they may have independent
pathophysiologic mechanisms. This is in contrast to
Flicker et al.,33 who detected an effect of tHcy lower-
ing on plasma A40. These differences may be re-
flective of the patient population (stroke patients
with high tHcy in the VISP study, community
dwelling older men in the study by Flicker et al.),
confounding by dietary changes in folate consump-
tion (VISP study), or differences in the form of A
measured by the assays (the assay used in this study
measures protein bound A, and does not detect oli-
gomeric forms). Additionally, given the definition of
the subcohort as those VISP subjects in the highest
quintile of tHcy at baseline, a component of the re-
duction of tHcy may represent regression to the
mean rather than vitamin effects.
The VISP study results may suggest that tHcy is
merely a marker for vascular disease and risk of cogni-
tive decline because tHcy lowering does not influence
A40 levels.9 Although tHcy is associated with plasma
A40, high dose vitamin treatment may differentially
impact these two plasma markers.4 Finally, correlations
between tHcy and other metabolites of the methylation
cycle, such as S-adenosylhomocysteine, have been re-
ported.34 How these metabolites respond to vitamin
treatment remains to be elucidated. Further epidemio-
logic and therapeutic studies investigating the relation-
ship between cerebrovascular disease and these
potentially important plasma biomarkers (tHcy and
A40, A42) are needed.
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